Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Beneficial owner of Pulmonx Boston Scientific sells over $28M in shares » 16:47
04/08/21
04/08
16:47
04/08/21
16:47
LUNG

Pulmonx

$45.49 /

-0.67 (-1.45%)

Beneficial owner of…

Beneficial owner of Pulmonx Boston Scientific disclosed in a filing that he had purchased 650,000 shares of company stock at $43.60 per share on April 6, for a total transaction amount of $28,340,000.

ShowHide Related Items >><<
LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

04/01/21 Citi
Pulmonx initiated with a Buy at Citi
03/25/21 Piper Sandler
Pulmonx initiated with a Neutral at Piper Sandler
03/10/21 BofA
Pulmonx upgraded to Buy from Neutral at BofA
03/03/21 Wells Fargo
Pulmonx price target raised to $56 from $46 at Wells Fargo
LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

  • 01
    Oct
LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

Hot Stocks
Beneficial owner of Pulmonx Boston Scientific sells over $28M in shares » 16:47
04/08/21
04/08
16:47
04/08/21
16:47
LUNG

Pulmonx

$45.49 /

-0.67 (-1.45%)

Beneficial owner of…

Beneficial owner of Pulmonx Boston Scientific disclosed in a filing that he had purchased 650,000 shares of company stock at $43.60 per share on April 6, for a total transaction amount of $28,340,000.

ShowHide Related Items >><<
LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

04/01/21 Citi
Pulmonx initiated with a Buy at Citi
03/25/21 Piper Sandler
Pulmonx initiated with a Neutral at Piper Sandler
03/10/21 BofA
Pulmonx upgraded to Buy from Neutral at BofA
03/03/21 Wells Fargo
Pulmonx price target raised to $56 from $46 at Wells Fargo
LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

  • 01
    Oct
LUNG Pulmonx
$45.49 /

-0.67 (-1.45%)

Initiation
Pulmonx initiated with a Buy at Citi » 06:42
04/01/21
04/01
06:42
04/01/21
06:42
LUNG

Pulmonx

$45.62 /

+1.79 (+4.08%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch initiated coverage of Pulmonx with a Buy rating and $60 price target. The company has revolutionized the treatment of severe emphysema for patients who, despite medical management, are symptomatic, Wuensch tells investors in a research note. The LIBERATE study demonstrated a significant improvement in lung function at 12 months, says the analyst. She sees a global total addressable market of $12B with the U.S. opportunity at $5B. Wuensch estimates Pulmonx treated 0.3% of the potential U.S. market in 2020, and forecasts it to reach 0.5% in 2021, 0.9% in 2022 and 1.4% in 2023.

ShowHide Related Items >><<
LUNG Pulmonx
$45.62 /

+1.79 (+4.08%)

LUNG Pulmonx
$45.62 /

+1.79 (+4.08%)

03/25/21 Piper Sandler
Pulmonx initiated with a Neutral at Piper Sandler
03/10/21 BofA
Pulmonx upgraded to Buy from Neutral at BofA
03/03/21 Wells Fargo
Pulmonx price target raised to $56 from $46 at Wells Fargo
03/03/21 Canaccord
Pulmonx price target raised to $65 from $49 at Canaccord
LUNG Pulmonx
$45.62 /

+1.79 (+4.08%)

  • 01
    Oct
LUNG Pulmonx
$45.62 /

+1.79 (+4.08%)

LUNG Pulmonx
$45.62 /

+1.79 (+4.08%)

Initiation
Pulmonx initiated with a Neutral at Piper Sandler » 04:56
03/25/21
03/25
04:56
03/25/21
04:56
LUNG

Pulmonx

$51.39 /

-1.07 (-2.04%)

Piper Sandler analyst…

Piper Sandler analyst Jason Bednar initiated coverage of Pulmonx with a Neutral rating and $50 price target. The company's category leadership in a "budding multi-billion dollar market opportunity" is already fully valued in the stock, Bednar tells investors in a research note.

ShowHide Related Items >><<
LUNG Pulmonx
$51.39 /

-1.07 (-2.04%)

LUNG Pulmonx
$51.39 /

-1.07 (-2.04%)

03/10/21 BofA
Pulmonx upgraded to Buy from Neutral at BofA
03/03/21 Wells Fargo
Pulmonx price target raised to $56 from $46 at Wells Fargo
03/03/21 Canaccord
Pulmonx price target raised to $65 from $49 at Canaccord
01/04/21 BofA
Pulmonx downgraded to Neutral from Buy at BofA
LUNG Pulmonx
$51.39 /

-1.07 (-2.04%)

  • 01
    Oct
LUNG Pulmonx
$51.39 /

-1.07 (-2.04%)

LUNG Pulmonx
$51.39 /

-1.07 (-2.04%)

Over a month ago
Upgrade
Pulmonx upgraded to Buy from Neutral at BofA » 06:52
03/10/21
03/10
06:52
03/10/21
06:52
LUNG

Pulmonx

$50.94 /

+0.85 (+1.70%)

BofA analyst Bob Hopkins…

BofA analyst Bob Hopkins upgraded Pulmonx to Buy from Neutral with a $72 price target.

ShowHide Related Items >><<
LUNG Pulmonx
$50.94 /

+0.85 (+1.70%)

LUNG Pulmonx
$50.94 /

+0.85 (+1.70%)

03/03/21 Wells Fargo
Pulmonx price target raised to $56 from $46 at Wells Fargo
03/03/21 Canaccord
Pulmonx price target raised to $65 from $49 at Canaccord
01/04/21 BofA
Pulmonx downgraded to Neutral from Buy at BofA
10/26/20 BofA
Pulmonx initiated with a Buy at BofA
LUNG Pulmonx
$50.94 /

+0.85 (+1.70%)

  • 01
    Oct
LUNG Pulmonx
$50.94 /

+0.85 (+1.70%)

LUNG Pulmonx
$50.94 /

+0.85 (+1.70%)

Recommendations
Pulmonx price target raised to $56 from $46 at Wells Fargo » 08:11
03/03/21
03/03
08:11
03/03/21
08:11
LUNG

Pulmonx

$57.93 /

-2.37 (-3.93%)

Wells Fargo analyst…

Wells Fargo analyst Lawrence Biegelsen raised the firm's price target on Pulmonx to $56 from $46 and keeps an Equal Weight rating on the shares. The analyst notes the company reported Q4 revenue of $9.8M which exceeded his estimate of $8.9M and consensus of $8.8M.

ShowHide Related Items >><<
LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

03/03/21 Canaccord
Pulmonx price target raised to $65 from $49 at Canaccord
01/04/21 BofA
Pulmonx downgraded to Neutral from Buy at BofA
10/26/20 BofA
Pulmonx initiated with a Buy at BofA
10/26/20 Canaccord
Pulmonx initiated with a Buy at Canaccord
LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

  • 01
    Oct
LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

Recommendations
Pulmonx price target raised to $65 from $49 at Canaccord » 07:11
03/03/21
03/03
07:11
03/03/21
07:11
LUNG

Pulmonx

$57.93 /

-2.37 (-3.93%)

Canaccord analyst William…

Canaccord analyst William Plovanic raised the firm's price target on Pulmonx to $65 from $49 and keeps a Buy rating on the shares. The analyst said the company continues to execute in a tough environment, adding new accounts in the US and expanding its commercial footprint at rates in line with expectations despite an increasing wave of COVID infections across the US.

ShowHide Related Items >><<
LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

01/04/21 BofA
Pulmonx downgraded to Neutral from Buy at BofA
10/26/20 BofA
Pulmonx initiated with a Buy at BofA
10/26/20 Canaccord
Pulmonx initiated with a Buy at Canaccord
10/26/20 Morgan Stanley
Pulmonx initiated with an Equal Weight at Morgan Stanley
LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

  • 01
    Oct
LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

LUNG Pulmonx
$57.93 /

-2.37 (-3.93%)

Earnings
Pulmonx reports Q4 EPS (27c), consensus (28c) » 16:03
03/02/21
03/02
16:03
03/02/21
16:03
LUNG

Pulmonx

$57.66 /

-2.64 (-4.38%)

Reports Q4 revenue…

Reports Q4 revenue $9.83M, consensus $8.81M. "In closing out 2020, we are encouraged by the demonstrable resilience of our business and underlying demand for the Zephyr Valve. Although we faced headwinds from COVID-19 through the fourth quarter and into the first two months of 2021, recent signals indicate that procedure volumes are now recovering," said Glen French, president and CEO. "With our expanded commercial footprint and the continued interest from patients and providers in the Zephyr Valve, we expect to reaccelerate growth as the pandemic subsides."

ShowHide Related Items >><<
LUNG Pulmonx
$57.66 /

-2.64 (-4.38%)

LUNG Pulmonx
$57.66 /

-2.64 (-4.38%)

01/04/21 BofA
Pulmonx downgraded to Neutral from Buy at BofA
10/26/20 BofA
Pulmonx initiated with a Buy at BofA
10/26/20 Canaccord
Pulmonx initiated with a Buy at Canaccord
10/26/20 Morgan Stanley
Pulmonx initiated with an Equal Weight at Morgan Stanley
  • 01
    Oct
LUNG Pulmonx
$57.66 /

-2.64 (-4.38%)

LUNG Pulmonx
$57.66 /

-2.64 (-4.38%)

Options
Six new option listings and one option delisting on February 4th » 08:30
02/04/21
02/04
08:30
02/04/21
08:30
AMR

Alpha Metallurgical Resources

$13.34 /

+0.34 (+2.62%)

, AVIR

Atea Pharmaceuticals

$88.32 /

+4.43 (+5.28%)

, FCAC

Falcon Capital Acquisition

$11.77 /

+0.205 (+1.77%)

, FST

Fast Acquisition

$10.99 /

-0.08 (-0.72%)

, LUNG

Pulmonx

$58.05 /

+0.35 (+0.61%)

, PDAC

Peridot Acquisition

$12.88 /

+0.245 (+1.94%)

, CTRA

Contura Energy

/

+

New option listings for…

New option listings for February 4th include Alpha Metallurgical Resources Inc (AMR), Atea Pharmaceuticals Inc (AVIR), Falcon Capital Acquisition Corporation (Class A Stock) (FCAC), FAST Acquisition Corp (Class A Stock) (FST), Pulmonx Corporation (LUNG), and Peridot Acquisition Corp (Class A Stock) (PDAC). Option delistings effective February 4th include Contura Energy Inc (CTRA).

ShowHide Related Items >><<
LUNG Pulmonx
$58.05 /

+0.35 (+0.61%)

FST Fast Acquisition
$10.99 /

-0.08 (-0.72%)

CTRA Contura Energy
/

+

AVIR Atea Pharmaceuticals
$88.32 /

+4.43 (+5.28%)

AMR Alpha Metallurgical Resources
$13.34 /

+0.34 (+2.62%)

AMR Alpha Metallurgical Resources
$13.34 /

+0.34 (+2.62%)

AVIR Atea Pharmaceuticals
$88.32 /

+4.43 (+5.28%)

01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
11/24/20 Morgan Stanley
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
11/24/20 JPMorgan
Atea Pharmaceuticals initiated with an Overweight at JPMorgan
FCAC Falcon Capital Acquisition
$11.77 /

+0.205 (+1.77%)

FST Fast Acquisition
$10.99 /

-0.08 (-0.72%)

LUNG Pulmonx
$58.05 /

+0.35 (+0.61%)

01/04/21 BofA
Pulmonx downgraded to Neutral from Buy at BofA
10/26/20 BofA
Pulmonx initiated with a Buy at BofA
10/26/20 Canaccord
Pulmonx initiated with a Buy at Canaccord
10/26/20 Morgan Stanley
Pulmonx initiated with an Equal Weight at Morgan Stanley
PDAC Peridot Acquisition
$12.88 /

+0.245 (+1.94%)

CTRA Contura Energy
/

+

07/10/20 Benchmark
Contura Energy downgraded to Hold on met coal price challenges at Benchmark
07/10/20 Benchmark
Contura Energy downgraded to Hold from Buy at Benchmark
06/09/20 B. Riley
B. Riley FBR downgrades Contura Energy after liquidity stress test
06/09/20 B. Riley
Contura Energy downgraded to Neutral from Buy at B. Riley FBR
CTRA Contura Energy
/

+

  • 30
    Oct
  • 01
    Oct
FST Fast Acquisition
$10.99 /

-0.08 (-0.72%)

LUNG Pulmonx
$58.05 /

+0.35 (+0.61%)

FCAC Falcon Capital Acquisition
$11.77 /

+0.205 (+1.77%)

AVIR Atea Pharmaceuticals
$88.32 /

+4.43 (+5.28%)

Over a quarter ago
Downgrade
Pulmonx downgraded to Neutral from Buy at BofA » 07:15
01/04/21
01/04
07:15
01/04/21
07:15
LUNG

Pulmonx

$68.92 /

+2.29 (+3.44%)

BofA analyst Bob Hopkins…

BofA analyst Bob Hopkins downgraded Pulmonx to Neutral from Buy.

ShowHide Related Items >><<
LUNG Pulmonx
$68.92 /

+2.29 (+3.44%)

LUNG Pulmonx
$68.92 /

+2.29 (+3.44%)

10/26/20 BofA
Pulmonx initiated with a Buy at BofA
10/26/20 Canaccord
Pulmonx initiated with a Buy at Canaccord
10/26/20 Morgan Stanley
Pulmonx initiated with an Equal Weight at Morgan Stanley
10/26/20 Stifel
Pulmonx initiated with a Buy at Stifel
  • 01
    Oct
LUNG Pulmonx
$68.92 /

+2.29 (+3.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.